New research suggests that genetic susceptibility to lung cancer is greater in women, and a family history of cancer predicts lung cancer risk.
Iruplinalkib, a novel ALK inhibitor, was more effective than crizotinib in a phase 3 trial of patients with advanced, ALK-positive non-small cell lung cancer.
Incidence rates of lung cancer subtypes vary across global regions, data suggest.
Researchers investigated the effects of multidisciplinary clinical management of IMDC in patients with NSCLC undergoing treatment with immune checkpoint inhibitors.
Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.